Stock screener

MYGN

Conviction 8HealthcareScan · Mon, Aug 10, 2026
MYGN$3.26+0.00%
ResistanceSupportVol 14Insider buyInsider sell
63 bars
Vol MA14 3.26M
May 11May 28Jun 16Jul 6Jul 23Aug 10
MYRIAD GENETICS INCIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESwww.myriad.com
Price3.26
Change+0.00%
Gap-1.07%
Rel volume1.39×
Avg volume2.53M
Avg $ vol9.4M
SMA 204.83
SMA 504.95
SMA 2005.45
Price vs 50-34.11%
Price vs 200-40.19%
MA stackbearish
50/200 cross
Supertrenddown · 4.39
RSI (14)29
MACD hist-0.24
MACD cross
Stoch %K / %D17 / 15
ADX (14)41
+DI / −DI12 / 41
RSI divergence
MACD divergence
ATR %+11.40%
ADR %6.07%
52w high8.18
52w low2.86
From 52w high-60.15%
Above 52w low+13.99%
New 52w highNo
SqueezeOff
Bollinger width106.51%
%B0.19
Donchian pos14.09%
Donchian high6.43
Donchian low2.74
AVWAP (52w high)5.05
vs AVWAP high-35.45%
AVWAP (52w low)3.10
vs AVWAP low+5.02%
OBV trendFlat
Chaikin MF (20)-0.12
Today vs 20d1.39×
Avg vol (14d)3.26M
Avg vol (20d)2.53M
Avg $ vol (20d)9.4M
Market cap
RS 3m (vs SPY)-25.99%
RS 6m (vs SPY)-50.19%
RS line new highNo
Trend template0/8
Technical rank9.3
1 week+7.95%
1 month-44.08%
3 months-24.01%
6 months-36.33%
1 year-46.56%
YTD-46.91%
P/E-0.85
P/B1.02
P/S0.38
P/FCF-7.16
EPS-3.95
Div yield
ROE-120.40%
ROA-57.27%
Debt/Eq0.59
Current2.21
EV/EBITDA-0.99
Gross margin69.93%
Net margin-44.38%
Rev growth-1.56%
EPS growth-187.43%
Price target4.68
Target upside43.78%
Analyst ratingHold
Institutional102.84%
Ent. value376.24M
Revenue190.7M
Net income-43.2M
Gross profit127M
Free cash flow-43.5M
IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
ExchangeNasdaq
Shares out94.45M
Employees2.7K
ListedFri, Oct 6, 1995
Free float
Float %
Short interest
Days to cover
Short volume
Squeeze score
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction8 / 100
Pattern quality
Tech rank9.3 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance6.34
Support3.57
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in MYGN

All disclosures →
No recent disclosed trades by Congress in MYGN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in MYGN · 9 buys · 1 sell

InsiderSideShares
Kumar Rashmi
Director · Common Stock · 2026-06-08
Sell15K
Dreismann Heinrich
Director · Common Stock · 2026-06-04
Grant59.7K
Bisaro Paul
Director · Common Stock · 2026-06-04
Grant59.7K
Newcomer Lee Nisley
Director · Common Stock · 2026-06-04
Grant59.7K
Davis Mark Steven
Director · Common Stock · 2026-06-04
Grant59.7K
Phanstiel S. Louise
Director · Common Stock · 2026-06-04
Grant59.7K
Kumar Rashmi
Director · Common Stock · 2026-06-04
Grant59.7K
Reitan Colleen F
Director · Common Stock · 2026-06-04
Grant59.7K
Skovronsky Daniel
Director · Common Stock · 2026-06-04
Grant59.7K
Jampa Raj
Chief Technology Officer · Common Stock · 2026-06-01
Grant251.89K

SEC filings

EDGAR filings in MYGN · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.